The Byk LIA-mat CA125 II assay was compared with the Centocor IRMA CA125 II. Serum samples studied (n ‫؍‬ 1012) were obtained from 652 apparently healthy females, 61 pregnant women, and 299 patients with benign and malignant gynecological tumors. The CA125 II assay value at the 95th percentile of the total healthy group was 29 kU/L for the LIA-mat and 32 kU/L for the Centocor assay. For the LIA-mat assay the 95th percentile was 31 kU/L (Centocor 36 kU/L) for the group <45 years and 21 kU/L (Centocor 25 kU/L) for women >55 years of age. By using ROC curves we found the optimal pretreatment Byk LIA-mat CA125 II value differentiating between benign and malignant ovarian tumors to be 95 kU/L. Pretreatment CA125 values >1000 kU/L were detected in serum samples of patients with advanced epithelial ovarian cancer.
After the introduction 12 years ago of the CA125 tumor marker assay, its use has become widespread in clinical practice [1] . Although the initial publications mainly focused on the monitoring of patients with epithelial ovarian carcinoma [2] , other applications were soon described. For example, Niloff et al. proposed to use it as an accessory to second-look laparoscopy [3] , and various authors introduced CA125 in the management of endometriosis [4] . Vasilev et al. included the serum assay values of this marker in the preoperative evaluation of pelvic masses [5] . However, as a diagnostic tool the CA125 antigen has a serious drawback as increased assay values have been found in a multitude of conditions (i.e., congestive heart failure [6] , liver cirrhosis [7] , and benign ovarian diseases [8, 9] ).
The OC 125 monoclonal antibody (mAb) was first described in 1981 [10] . 5 It was obtained by immunizing BALB/c mice with the OVCA 433 cell line isolated from the ascites of a patient with serous papillary cystadenocarcinoma. Previously, CA125 II assays were introduced in which the CA125 capture antibody is murine mAb M11, with a higher avidity for epitopes of the CA125 molecule [11] .
An extensive evaluation of technical aspects of the Byk LIA-mat CA125 II has been published recently [12] . To assess the impact of this newly developed sandwich assay for clinical practice, we carried out a comparative study with second-generation CA125 II assay with clinical data, in particular with the use of reference values.
Materials and Methods assay procedures
The LIA-mat CA125 II (Byk-Sangtec, Dietzenbach, Germany) is a heterologous assay with M11 as the solidphase (coated tube)-bound capture mAb and OC 125 as tracer mAb, covalently labeled with an isoluminol derivative. The light signal is proportional to the amount of CA125 antigen in the sample.
The LIA-mat assays were processed on a LIA-mat 300 System [13] .
The Centocor ® CA125 II (Centocor, Malvern, PA) is a one-step "sandwich" IRMA involving polystyrene beads coated with the M11 mAb as solid phase. The tracer is the 125 I-labeled murine mAb OC 125. Day-to-day CV for the Byk LIA-mat assay was 10.4% at 215 kU/L and 11.2% at 75 kU/L. The Centocor CA125 II day-to-day precision was 10.0% at 180 kU/L and 12.2% at 66 kU/L. All tests were performed in duplicate according to the manufacturer's instructions, and reference sera were included with each batch. Blood, not processed immediately, was centrifuged within 1 h and the serum was stored at Ϫ20°C the same day.
Tumors were staged according to the International Federation of Gynecology and Obstetrics (FIGO) classification for gynecological cancer [14] .
sample collection CA125 was determined retrospectively in a total of 1012 serum samples: Group A (n ϭ 652). Apparently healthy women, age Ն40 years, who volunteered to take part in a screening program for early detection of ovarian cancer were included when no abnormalities were found after they underwent pelvic examination, including an ultrasound scan. Mean age was 49 with a maximum of 76 years.
Group B (n ϭ 61).
Blood from women with an uneventful pregnancy was collected in a maternity clinic. The available sample was used when informed consent was given. Twenty of the women were in the first trimester, 21 in the second trimester, and 20 in the third trimester of their pregnancy. Ages were 24 -44 years (mean 33 years).
Group C (n ϭ 134).
Patients with benign pelvic diseases who were operated on in the Departments of Obstetrics and Gynecology of the Academic Hospital of the Free University were included when they gave informed consent.The following benign ovarian tumors were pathologically established: (a) serous cystadenoma (n ϭ 35), (b) mucinous cystadenoma (n ϭ 18), (c) fibroadenoma (n ϭ 8), (d) dermoid cyst (n ϭ 10), and other benign pelvic tumors (n ϭ 63). Mean age was 44 years, with a range of 14 -84 years.
Group D (n ϭ 165). Sera available from patients diagnosed with primary malignant gynecological tumors from 1985 to 1993: (a) cervix (n ϭ 23): stage I/II (n ϭ 12) (adenocarcinoma n ϭ 5, squamous cell n ϭ 6), stage III/IV (n ϭ 11) (adenocarcinoma n ϭ 7, squamous cell n ϭ 7); (b) endometrium (n ϭ 57): stage I/II (n ϭ 45), stage III/IV (n ϭ 8); (c) ovary (n ϭ 85): stage I/II (n ϭ 26) (epithelial n ϭ 21, nonepithelial n ϭ 4), stage III/IV (n ϭ 59) (epithelial n ϭ 58, nonepithelial n ϭ 1).
statistics
Because of the marked skewed distribution and the large overall range of the CA125 values, these were logarithmically transformed before any analysis, resulting in reasonable normality of residuals and constancy of variance. The relation between CA125 values and age in healthy women was studied by using restricted cubic spline regression analysis [15] . To compare the two assay methods, the difference of the result was plotted against the corresponding mean after logarithmic transformation. To identify outliers, residual analyses were performed. Variances were compared with Bartlett's test. Normality was checked by inspecting normal probability plots with the Shapiro-Francia test, or occasionally the Shapiro-Wilk test, and quantified by Royston's V [16] . To assess the test performance characteristics of the assays, the sensitivity and specificity at maximal overall test accuracy were calculated. Maximal overall test accuracy, defined as the shortest distance from the upper left corner of a ROC curve, was derived from actual ROC curves. ROC curves were constructed according to the NCCLS guidelines [17] and were evaluated by calculating and comparing areas under the curves (AUCs) according to DeLong et al. [18] . The SAS 6.10 (Windows) package was used for the main analyses.
Results

assay comparison
A comparison between the results of the Byk CA125 II and the Centocor CA125 II assay was made by using the difference plot ( Fig. 1 ) [19] . Differences of logarithmically transformed values of 1012 samples were plotted against the average value of both assays. The Byk assay presented lower results in the lower calibrator range and somewhat higher values at concentrations Ͼ90 kU/L (ln 4.5).
distribution of ca125 values
Healthy controls (n ϭ 652). The distribution of CA125 values in the healthy control population is nongaussian and skews positively. The relation between Byk LIA-mat CA125 values after back-transformation to the linear scale and age is depicted in Fig. 2 . The predicted values (central line) and 95% prediction limits (outer lines), according to the restricted spline method, are indicated. There is evi- dence for nonlinearity (P ϭ 0.0004): relatively constant values up to age 45, then a decrease until age 55. After age 55, the CA125 values seem to stabilize again. The variation around the straight line of the normal plot is higher (as could be expected from chance alone), the main problem being a larger-than-expected group of females at the lower end (studentized residual around Ϫ3). Results of the analyses of the Byk LIA-mat assay were equivalent to the Centocor assay. On the basis of the aforementioned results, we have partitioned the healthy women in age groups of Ͻ45, 45-55, and Ͼ55 years. A description of the CA125 values is given in Table 1 . The 95th percentile of the group Ͻ45 years is 31 kU/L for the Byk LIA-mat and 36 kU/L for the Centocor test assay, decreasing to 21 kU/L and 25 kU/L for the group Ͼ55 years (P Ͻ0.001), respectively. The 99th percentile of the same age groups showed a difference of 8 kU/L (P Ͻ0.001): 33 kU/L for the Byk LIA-mat assay and 25 kU/L for the Centocor. The upper limit of normal (95%) for the whole population should have been 29 kU/L for the Byk assay and 32 kU/L for the Centocor assay.
Patients. 1) Pregnancy samples (n ϭ 61). A median serum CA125 value of 19 kU/L was found with a highest value of 80 kU/L with the Byk LIA-mat (87 kU/L for Centocor). Concentrations Ͼ35 kU/L were present in 13 cases (21%). However, 16 females (26%) had a concentration Ͼ31 kU/L, the 95th percentile for the appropriate age group. The percentage decreased to 16% (10 of 61) when using the corresponding 32 kU/L found with the Centocor assay.
2) Benign pelvic diseases (n ϭ 134). For patients with benign pelvic disease, the Byk assay values are on average lower than the Centocor results. This group had a median Byk LIA-mat CA125 II concentration of 22 kU/L with values from 3 to 483 kU/L. Twenty-six percent of the patients had a marker concentration Ͼ35 kU/L. Applying 29 kU/L as a cutoff concentration, 35% of the tested samples were found to have increased values. There was some evidence of a difference between the five histological groups of benign ovarian tumors (P ϭ 0.026). However, there was a rather large variation observed for the calibrated residual SD. Results of the nonparametric Kruskal-Wallis test showed no significant difference (P ϭ 0.07). The median Centocor CA125 II value was 27 kU/L with a range of 5-475 kU/L. Twenty-seven percent of the Centocor CA125 II values were Ͼ35 kU/L, and 37% were above the 95th percentile value of 32 kU/L. 3) Gynecological malignancies (n ϭ 449). CA125 assay values in serum from patients with different gynecological malignancies and different clinical stages of ovarian carcinoma were determined (Table 2) . Very high concentrations of the CA125 antigen mainly occurred in cases of ovarian carcinomas. Measured with the LIA-mat CA125 II assay, the median values in the latter group were 116 kU/L for FIGO stage I/II and 1290 kU/L for stage III/IV, significantly differing from each other (P Ͻ0.001). This difference is still valid after correction for variations in histology in the different stage groups. These results hold for the Centocor CA125 II test results as well. A scatterplot of the CA125 assay values measured in serum from patients with different gynecological malignancies as determined with the Byk LIA-mat shows that in nonovarian cancer, concentrations Ͼ100 kU/L are less common and serum assay values Ͼ1000 kU/L are rare (Fig. 3) . (Fig. 5) . From the ROC curves, the point at the line having the shortest distance to the upper left corner (100% sensitivity, 100% specificity) was calculated. At this concentration the test reaches its optimal accuracy in terms of discriminating the evaluated patient groups. In Table 3 the CA125 values with corresponding sensitivity and specificity are given. Both assays show a highly similar sensitivity and specificity spectrum. Optimal test accuracy to discriminate between healthy females and a group of patients with benign pelvic disease was found at concentrations of 15 and 20 kU/L for the Byk and Centocor assay, respectively. A specificity rate of 90% is reached at concentrations of 24 and 27 kU/L, close to the reported reference concentrations calculated for the healthy controls. The corresponding sensitivity to find the disease is, however, only ϳ50%. The ROC curve constructed on the basis of patients with benign pelvic disease and those patients with ovarian carcinoma displays a similar pattern for both assays (Fig.  5) . Optimal test accuracy to discriminate malignant disease from benign tumors is found at 95 kU/L. This is virtually corresponding to the 90% specificity point. The two CA125 assays reach a sensitivity of little over 60% at this specificity concentration. The sensitivity to detect malignancy in this patient group is increased to 90% at concentrations of 28 and 31 kU/L for the Byk and Centocor assays, respectively. This will result in almost 40% of the results being falsely considered positive.
Discussion
The introduction of a new generation of CA125 assays has led to several investigations comparing the original homologous two-site "sandwich" assay based on a single mAb (OC 125) with the previously developed assays that incorporate the OC 125 and the M11 mAbs [20, 21] . The Bland-Altman difference plot indicates that the Byk assay reveals a negative deviation at the lower end of the calibrator range. This bias has implications for the distribution of values in the various groups studied. In earlier publications we demonstrated a good overall correlation between all the CA125 tests studied, but also noted that differences in the lower range could occur [12, 20] . It is customary to use a 95th percentile interval as a reference range [22] ; this interval is usually established between the 2.5th and 97.5th percentiles. However, for tumor markers there are no lower limits for a healthy population, and therefore the upper reference value is set at the 95th percentile. In this study the 95th percentile of CA125 serum values in a group of 652 healthy women used as a control group was 29 kU/L for the Byk LIA-mat and 32 kU/L for the Centocor assay, concentrations clearly lower than the 35 kU/L given in the package inserts. The reference value currently in use was introduced by Bast et al. [2] , arbitrarily set from the 99th percentile of test results for a group of 888 blood donors, including 537 males. A previous overview of studies reporting reference values showed that 2.5% of Ͼ10 000 apparently healthy women had concentrations Ͼ35 kU/L [23] . In this study we demonstrated nonlinearity in the distribution of serum CA125 values and a significant relation between age and CA125 serum concentrations. The 95% prediction limits of the mean value after logarithmic transformation prompted us to divide the population of healthy women into three age groups. In the group of women over age 55 years, none had a serum CA125 concentration Ͼ35 kU/L. This is a strong argument for not applying a common reference range to the whole female population, as is also suggested by Bon et al. [24] . We find a reference range of Premenopausal values of CA125 may exceed 100 kU/L. This is in agreement with publications indicating that increased concentrations of this antigen may occur in the follicular phase of the cycle, particularly during menstruation [25] . The measurement of CA125 concentrations has been considered of limited value in screening procedures, the low predictive value of the test being the main obstacle for its applicability [26] . However, most studies find that the sensitivity and specificity are better in postmenopausal women as compared with premenopausal women. A careful application of age-adjusted cutoff concentrations may further improve the identification of subgroups with a high risk for epithelial ovarian carcinoma.
The test results of both assays for the group of patients with benign ovarian tumors are strikingly identical: The Byk assay showed 26% and the Centocor assay showed 27% with serum concentrations Ͼ35 kU/L. Di-Xia et al. [8] measured CA125 concentrations Ͼ35 kU/L in 35% of their group of patients with benign ovarian tumors, comparable with our findings when related to the adjusted cutoff concentrations. However, positivity rates of 5% (2 of 41) and 10% (3 of 31) were reported by Einhorn et al. [27] and Vasilev et al. [5] , respectively. Several reasons can explain this difference: The various assays used in these studies do not correlate exactly and the size and composition of the patient groups are different. Di-Xia et al. described a group of patients with a majority having cystadenomas, whereas the Einhorn et al. population was not further characterized. The fact that no significant difference in serum CA125 concentrations was found between the patients with pelvic disease and the group with benign ovarian tumors may point to the plausibility that the increase of CA125 concentrations is not derived from the release of the antigen from the benign tumor but from the shedding of CA125 from surrounding irritated peritoneal tissue.
It is evident that further information on the age distribution of patients and control groups might help to explain the observed differences. Application of ROC curves could further diminish the impact of possible disparities in the CA125 assays used. The CA125 assay cannot achieve discrimination between healthy females and the group with benign pelvic diseases, as the predictive value reaches only 50% at optimal test accuracy concentrations.
The pretreatment serum CA125 assay values in our group of patients with gynecological malignancies are in agreement with earlier reports. The serum CA125 assay values of patients with endometrial carcinoma are increased in 25% of the cases Ͼ35 kU/L. The same percentage is reported by Kenemans et al. [23] ; moreover, ϳ30% of patients with cervical carcinoma were reported to have an increased serum CA125 concentration. In this study we found increased values in 39% of the pretreatment sera obtained from patients with cervical cancer, probably due to a higher tumor load in patients classified in higher FIGO stages. The sensitivity for detecting epithelial ovarian carcinoma is comparable for both assays if the cutoff concentration is adjusted to the legitimate 95th percentile. A study to assess the effect of an age-related reference range to possibly improve the sensitivity for low-stage disease is required. We calculated optimal CA125 assay values by ROC curve analysis and correlated optimal sensitivity and specificity in a given clinical situation. The obtained results indicate that each assay has a typical cutoff value for distinguishing specific subgroups of patients. Because CA125 is frequently used as one of the parameters for diagnosing pelvic masses, the choice of the cutoff value is important [8, 28] .
In conclusion, the new LIA-mat CA125 II assay has a high correlation with the Centocor CA125 II IRMA, generally regarded as the reference assay for the measurement of CA125 in serum. There are, however, slight differences, and results are not simply transferable. Therefore, to acquire insight into the performance of the assay in use, we recommend participation in an external quality-control assessment scheme.
